Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Operating Expenses (2018 - 2025)

Entera Bio has reported Operating Expenses over the past 8 years, most recently at $3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 30.17% year-over-year to $3.0 million, compared with a TTM value of $11.5 million through Dec 2025, up 20.17%, and an annual FY2025 reading of $11.5 million, up 20.17% over the prior year.
  • Operating Expenses came in at $3.0 million for Q4 2025, down from $3.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $4.1 million in Q4 2021 to a low of $2.0 million in Q4 2023.
  • Median Operating Expenses over the past 5 years was $2.6 million (2021), compared with a mean of $2.8 million.
  • The sharpest move saw Operating Expenses soared 74.82% in 2021, then plummeted 42.53% in 2023.
  • Over 5 years, Operating Expenses stood at $4.1 million in 2021, then fell by 25.33% to $3.1 million in 2022, then tumbled by 36.14% to $2.0 million in 2023, then grew by 19.05% to $2.3 million in 2024, then soared by 30.17% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Operating Expenses are $3.0 million (Q4 2025), $3.3 million (Q3 2025), and $2.7 million (Q2 2025).